United States Food and Drug Administration (USFDA) conducted a CGMP inspection at SMS Pharmaceuticals’ Kandivalasa, Vizianagaram, Andhra Pradesh API manufacturing facility from January 13, 2020 to January 17, 2020. The inspection ended with two observations which are procedural in nature and correctable.
SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.